Gene: AGGF1
Official Full Name: angiogenic factor with G-patch and FHA domains 1provided by HGNC
Gene Summary: This gene encodes an angiogenic factor that promotes proliferation of endothelial cells. Mutations in this gene are associated with a susceptibility to Klippel-Trenaunay syndrome. Pseudogenes of this gene are found on chromosomes 3, 4, 10 and 16.[provided by RefSeq, Sep 2010]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00415 | AGGF1 Knockout cell line (HeLa) | Human | AGGF1 | 1:3~1:6 | Negative | Online Inquiry |
KO19940 | AGGF1 Knockout cell line (HCT 116) | Human | AGGF1 | 1:2~1:4 | Negative | Online Inquiry |
KO19941 | AGGF1 Knockout cell line (HEK293) | Human | AGGF1 | 1:3~1:6 | Negative | Online Inquiry |
KO19942 | AGGF1 Knockout cell line (A549) | Human | AGGF1 | 1:3~1:4 | Negative | Online Inquiry |
AGGF1 Gene Knockout Cell Lines are genetically engineered cell lines in which the AGGF1 gene, a critical player in angiogenesis and vascular development, has been specifically disrupted. This knockout model enables researchers to study the physiological and pathological roles of AGGF1 more effectively, providing insights into its involvement in various biological processes and diseases.
The primary function of AGGF1, also known as Angiogenic Factor with G-Patch and FHA Domains 1, is to regulate endothelial cell function and promote angiogenesis, which is the formation of new blood vessels. By creating AGGF1 knockout cell lines, scientists can investigate the downstream effects that the absence of this gene has on cellular signaling pathways and morphological changes in endothelial cells. This is particularly valuable in understanding conditions such as cancer, where aberrant angiogenesis contributes to tumor growth and metastasis.
In both research and clinical applications, AGGF1 gene knockout cell lines serve as robust tools for drug discovery and functional studies. They offer an unparalleled opportunity to assess the efficacy of novel therapeutics aimed at modulating angiogenic pathways. Moreover, understanding the involvement of AGGF1 in various disorders—including cardiovascular diseases and diabetic complications—provides a potential avenue for developing targeted interventions.
What sets AGGF1 Gene Knockout Cell Lines apart from traditional models is their precise genetic modification, which allows for reproducible and relevant experimental outcomes. Compared to non-targeted methods or wild-type models, these knockout lines provide clear advantages in terms of specificity and accuracy in research findings.
For researchers and clinicians aiming to pioneer advancements in vascular biology and therapeutic interventions, AGGF1 Gene Knockout Cell Lines represent an invaluable resource. They empower insights into complex biological systems while opening new avenues for targeted therapies.
At [Your Company Name], we specialize in providing high-quality, customized biological products, ensuring our clients have the tools they need to push the boundaries of scientific research and innovation. Our expertise in genetic engineering and commitment to quality make us a trusted partner in your research endeavors.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.